TB CRE Research Objectives 2024-2029​

​

The goal of the “CRE to End TB on both sides of the border” is to fill the key evidence gaps in the drive to finally end TB as a global health problem. We will achieve this goal by developing and evaluating new strategies to detect, treat and prevent TB in Australia and across the Indo-Pacific region.

​

We are fulfilling our mission by accomplishing six key objectives:

​

1. Enhance the diagnosis of TB, focusing on early TB. We will generate new knowledge about the biology of early ‘subclinical’ TB and extend this to mass screening strategies in high-burden settings.

2. Improve the safety, duration and tolerability of TB treatment. We will develop new safer and shorter treatment through pre-clinical studies, pharmacokinetic analysis and clinical trials - for drug-resistant and drug-susceptible TB, including individualized therapies.

3. Prevent the development of TB. We will develop new vaccines and evaluate them in clinical trials in the region. We will also conduct Phase 2 & 3 trials of new TB preventive treatments.